These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16965950)

  • 1. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
    Lin Y; Bruyère H; Horsman DE; Pantzar T; Barnett MJ; Hogge DE; Nevill TJ; Nantel SH; Sutherland HJ; Toze CL; Shepherd JD; Lavoie JC; Song KW; Smith CA; Forrest DL
    Cancer Genet Cytogenet; 2006 Oct; 170(1):16-23. PubMed ID: 16965950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
    Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
    Terre C; Eclache V; Rousselot P; Imbert M; Charrin C; Gervais C; Mozziconacci MJ; Maarek O; Mossafa H; Auger N; Dastugue N; Talmant P; Van den Akker J; Leonard C; N'Guyen Khac F; Mugneret F; Viguié F; Lafage-Pochitaloff M; Bastie JN; Roux GL; Nicolini F; Maloisel F; Vey N; Laurent G; Recher C; Vigier M; Yacouben Y; Giraudier S; Vernant JP; Salles B; Roussi J; Castaigne S; Leymarie V; Flandrin G; Lessard M;
    Leukemia; 2004 Aug; 18(8):1340-6. PubMed ID: 15190256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.
    Navarro JT; Feliu E; Grau J; Espinet B; Colomer D; Ribera JM; Oriol A; Granada I; Juncà J; Millá F
    Am J Hematol; 2007 Sep; 82(9):849-51. PubMed ID: 17563075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
    Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
    Zámecníkova A; Al Bahar S; Ramesh P
    Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
    Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
    Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Ph-negative abnormal clones emerging during imatinib therapy.
    Abruzzese E; Gozzetti A; Galimberti S; Trawinska MM; Caravita T; Siniscalchi A; Cervetti G; Mauriello A; Coletta AM; De Fabritiis P
    Cancer; 2007 Jun; 109(12):2466-72. PubMed ID: 17503437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
    Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
    Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
    Mohamed AN; Pemberton P; Zonder J; Schiffer CA
    Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.
    Holzerová M; Faber E; Veselovská J; Urbánková H; Balcárková J; Rozmanová S; Voglová J; Muzík J; Chroust K; Indrák K; Jarosová M;
    Cancer Genet Cytogenet; 2009 May; 191(1):1-9. PubMed ID: 19389502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
    Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
    Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts.
    Kondo T; Tasaka T; Sano F; Matsuda K; Kubo Y; Matsuhashi Y; Nakanishi H; Sadahira Y; Wada H; Sugihara T; Tohyama K
    Leuk Res; 2009 Sep; 33(9):e137-8. PubMed ID: 19371951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
    Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?
    O'Shea D; Crotty G; Carroll P; Conneally E; McCann S; Neat MJ
    Br J Haematol; 2004 Nov; 127(3):367-9. PubMed ID: 15491304
    [No Abstract]   [Full Text] [Related]  

  • 18. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
    Medeiros BC; Chun K; Kamel-Reid S; Lipton J
    Am J Hematol; 2007 Aug; 82(8):758-60. PubMed ID: 17301975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trisomy 8 in Philadelphia-negative cells during imatinib therapy.
    Bernardeschi P; Fiorentini G; Rossi S; Dentico P; Simi P; Guidi S
    Am J Hematol; 2004 Sep; 77(1):88-9. PubMed ID: 15307114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clonal Ph-negative hematopoiesis with trisomy 8 in chronic myeloid leukemia during imatinib therapy].
    Yamamoto Y; Ishii K; Nomura S; Fukuhara S
    Rinsho Ketsueki; 2004 Feb; 45(2):164-6. PubMed ID: 15045827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.